Inhibition of VEGF signal transduction. Identification of ZD4190.
Wedge
S R
SR
Cancer and Infection Research Department, AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, U.K.
Ogilvie
D J
DJ
D000970:Antineoplastic Agents / Q000494:pharmacology*; D016228:Endothelial Growth Factors / Q000378:metabolism*; D006801:Humans; D008222:Lymphokines / Q000378:metabolism*; D011799:Quinazolines / Q000494:pharmacology*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors*; D040262:Receptors, Vascular Endothelial Growth Factor; D015398:Signal Transduction; D014230:Triazoles / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000970:Antineoplastic Agents; D016228:Endothelial Growth Factors; D008222:Lymphokines; D011799:Quinazolines; D017978:Receptors, Growth Factor; D014230:Triazoles; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C405268:ZD 4190; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor